Eli Lilly vs. Novo: The Hidden Battle Behind the Weight-Loss Platform Reshaping Industries
GLP-1 is a drug platform, not one product. Lilly leads; Novo slips; Pfizer, Amgen, Roche, and AbbVie chase, with pricing, generic and trial risks.
Barchart ·